Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 3, 2017

Primary Completion Date

August 17, 2021

Study Completion Date

August 17, 2021

Conditions
Severe Aplastic Anemia
Interventions
DRUG

Antithymocyte Globulin (ATG)

Administration of ATG will be 0.5 mg/kg IV on Day -9 over 6 hours and 2 mg/kg IV on Days -8 and -7 over 4 hours.

DRUG

Fludarabine

Fludarabine dose will be 30 mg/m\^2 IV daily for 5 days from Day -6 to Day -2.

DRUG

Cyclophosphamide

Cyclophosphamide dose will be 14.5 mg/kg IV daily for 2 days (Day -6 to Day -5) prior to transplantation and 50 mg/kg IV daily for 2 days (Day +3 to Day +4) after transplantation.

RADIATION

Total Body Irradiation (TBI)

TBI is to be delivered in a single dose of 200 cGy on Day -1.

PROCEDURE

Haplo HSCT

Eligible patients without a fully matched related or unrelated donor available will undergo haploidentical bone marrow transplant.

DRUG

Tacrolimus

Tacrolimus should be started on Day +5 and administered to maintain a level of 10-15 ng/mL.

DRUG

Mycophenolate mofetil (MMF)

MMF dose will be 15 mg/kg PO three times a day (TID) up to 1 gm TID (or IV equivalent) starting on Day +5.

DRUG

G-CSF

G-CSF will be given IV or SQ starting on Day +5 at 5 mcg/kg/day until ANC is \> 1500 for 3 days.

Trial Locations (28)

14263

Roswell Park Cancer Institute, Buffalo

17033

Penn State College of Medicine/The Milton S. Hershey Medical Center, Hershey

19104

University of Pennsylvania Cancer Center, Philadelphia

20010

Children's National Medical Center, Washington D.C.

21231

Johns Hopkins Unversity, Baltimore

27705

Duke University Medical Center, Durham

30342

Northside Hospital, Atlanta

32610

University of Florida College of Medicine, Gainesville

33155

Miami Children's Hospital, Miami

33624

H. Lee Moffitt Cancer Center, Tampa

33701

All Children's Hospital, St. Petersburg

40202

University of Louisville/Kosair Children's Hospital, Louisville

46202

Indiana University Medical Center/ Riley Hospital for Children, Indianapolis

48105

University of Michigan Medical Center, Ann Arbor

48201

Karmanos Cancer Institute/Children's Hospital of Michigan, Detroit

53211

Children's Hospital of Wisconsin/Midwest Children's Cancer, Milwaukee

63110

Washington University/Barnes Jewish Hospital, St Louis

64108

Children's Mercy Hospital and Clinics, Kansas City

77030

Baylor College of Medicine, Houston

University of Texas/MD Anderson Cancer Center, Houston

78229

Texas Transplant Institute, San Antonio

90027

Children's Hospital of Los Angeles, Los Angeles

91010

City of Hope National Medical Center, Duarte

94305

Stanford Hospital and Clinics, Stanford

94618

Children's Hospital and Research Center Oakland, Oakland

98109

Fred Hutchinson Cancer Research Center, Seattle

07601

Hackensack University Medical Center, Hackensack

97239-3098

Oregon Health and Science University, Portland

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Blood and Marrow Transplant Clinical Trials Network

NETWORK

collaborator

National Marrow Donor Program

OTHER

lead

Medical College of Wisconsin

OTHER

NCT02918292 - Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502) | Biotech Hunter | Biotech Hunter